The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Carl Schmidt joins WVU Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Carl Schmidt, a surgical oncologist specializing in cancers of the liver, pancreas, and stomach, will join the West Virginia University Cancer Institute in July.

Schmidt will serve chief of surgical oncology and surgeon in chief of the WVU Cancer Institute. He plans to grow the program’s capacity to serve a larger number of patients and offer more innovative surgeries through fostering relationships across the state.

Schmidt comes to WVU from the Ohio State University College of Medicine Wexner Medical Center, where he served as associate professor of surgery. At Ohio State, he also served as vice chair of quality and patient safety and program director for surgical oncology fellowships.

Schmidt’s scholarly work focuses on outcomes for patients with gastrointestinal cancers and quality of care for cancer patients.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Sponsored

Meeting the moment: ASCO GI Cancers Symposium delivers insights and collaboration

When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.
By The American Society of Clinical Oncology
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account